Schrödinger Enters into a Multi-Target Collaboration and Expanded Software Licensing Agreement with Novartis
Shots:
- Schrödinger & Novartis have signed a research collaboration & licensing agreement to advance latter’s drug candidates and also expanded a 3-year software agreement, providing Novartis access to Schrödinger’s computational modeling & drug discovery tech across its research sites
- The companies will select & advance therapeutics for undisclosed targets in Novartis’s key areas. Both will share discovery efforts, with Novartis handling clinical development, manufacturing & commercialization
- Schrödinger will receive $150M upfront, up to $892M research, development & regulatory milestones, additional $1.38B commercial milestones plus tiered mid-single-digit to low-double-digit net-sales-based royalties per product commercialized by Novartis
Ref: Schrödinger | Image: Novartis & Schrödinger
Related News:- The US FDA Approves Novartis’ Scemblix for Newly Diagnosed Ph+ CML in Chronic Phase
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
